Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry, immunofluorescence, and glycobiology. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
IPO Year: 2020
Exchange: NASDAQ
Website: maravai.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2025 | $9.00 → $3.00 | Outperform → Neutral | Robert W. Baird |
| 12/19/2024 | Neutral | Guggenheim | |
| 12/5/2024 | $4.25 | Neutral → Sell | Goldman |
| 11/14/2024 | Peer Perform | Wolfe Research | |
| 11/8/2024 | Outperform → Mkt Perform | William Blair | |
| 8/28/2024 | $10.00 | Overweight | Wells Fargo |
| 8/13/2024 | $11.00 → $10.00 | Overweight → Equal-Weight | Morgan Stanley |
| 4/10/2024 | $15.00 | Buy | Craig Hallum |
| 12/12/2023 | $10.00 → $8.00 | Neutral → Buy | BofA Securities |
| 8/8/2023 | Overweight → Sector Weight | KeyBanc Capital Markets |
8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
SCHEDULE 13G - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
S-8 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
10-Q - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
DEF 14A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
10-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)
SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William "Trey" Martin III in these roles. "This leadership transition reflects Maravai's commitment to accelerating innovation, execution, and financial performance. Bernd brings more than 30 years of leadership experience in the life sciences industry, with a proven track record of transforming businesses into profitable, revenue-growing com
Quantoom's customers can now access TriLink's CleanCap mRNA capping technology; Agreement supports future expansion of essential therapeutics & vaccines in developing countries & regions TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ:MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Under the agreement, Quantoom will have access to TriLink's CleanCap® mRNA capping technology for integration in its Ntensify® (sa)mRNA production platform to help accelerate the RNA production process and ma
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of "Maravai LifeSciencesReleases 2024 Sustainability Report". The corrected title is "Maravai LifeSciences Releases 2024 Sustainability Report". Maravai Lif
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2
New all-in-one IVT kit can deliver up to 2X more mRNA and up to 85% lower dsRNA compared to other kits on the market through streamlined mRNA synthesis with efficient capping, increased yield, reduced dsRNA, and enhanced performance TriLink BioTechnologies® (TriLink®), a Maravai® LifeSciences company (NASDAQ:MRVI), is fueling the future of mRNA research — starting with a significant donation to top academic labs across the U.S. and Europe. The donation commemorates the launch of TriLink's first mRNA synthesis kit featuring CleanCap® capping technology, an all-in-one kit with its innovative products in one box at a competitive price. Seven academic institutions will receive ten kits each t
Today, TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ:MRVI) and global provider of life science reagents and services, and the International Vaccine Institute (IVI), a non-profit international organization devoted to and the discovery, development and delivery of vaccines for global health signed a Memorandum of Understanding to collaborate to advance the research and development of mRNA-based vaccines and promote equitable access to essential vaccines and health technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514331075/en/Dr. Jerome Kim, Director General of IVI (left), standing next t
SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Highlights: Quarterly revenue of $46.9 million, Net loss of $(52.9) million (including a goodwill impairment of $12.4 million), and Adjusted EBITDA of $(10.5) million; andRevenue for the full year 2025 is expected to be in the range of $185.0 million to $205.0 million, unchanged from previous guidance. "Our first quarter revenue exceeded our guidance range, an
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2025 financial and operating results after the market close on Monday, May 12, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 343-4849 or (203) 518-9848 and reference Maravai LifeSciences, Conference ID MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com.
SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2024, together with other business updates. The company also expects to file its Annual Report on Form 10-K for the year ended December 31, 2024, with the Securities and Exchange Commission today. Upon filing, a copy of the annual report will be available on Maravai's website, www.maravai.com, by selecting "Investors" and then "SEC Filings." Key Financial Results: Quarterly revenue of $56.6 million, Ne
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that it is postponing its previously announced earnings release and call scheduled for February 25, 2025. It also announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission and will delay the filing its annual report on Form 10-K for the fiscal year ended December 31, 2024 (the "2024 Form 10-K"). Maravai intends to hold its postponed earnings call and to file the 2024 Form 10-K as soon as practicable and on or
Robert W. Baird downgraded Maravai Life Sciences from Outperform to Neutral and set a new price target of $3.00 from $9.00 previously
Guggenheim initiated coverage of Maravai Life Sciences with a rating of Neutral
Goldman downgraded Maravai Life Sciences from Neutral to Sell and set a new price target of $4.25
Wolfe Research initiated coverage of Maravai Life Sciences with a rating of Peer Perform
William Blair downgraded Maravai Life Sciences from Outperform to Mkt Perform
Wells Fargo initiated coverage of Maravai Life Sciences with a rating of Overweight and set a new price target of $10.00
Morgan Stanley downgraded Maravai Life Sciences from Overweight to Equal-Weight and set a new price target of $10.00 from $11.00 previously
Craig Hallum initiated coverage of Maravai Life Sciences with a rating of Buy and set a new price target of $15.00
BofA Securities upgraded Maravai Life Sciences from Neutral to Buy and set a new price target of $8.00 from $10.00 previously
KeyBanc Capital Markets downgraded Maravai Life Sciences from Overweight to Sector Weight
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)
SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)
SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Highlights: Quarterly revenue of $46.9 million, Net loss of $(52.9) million (including a goodwill impairment of $12.4 million), and Adjusted EBITDA of $(10.5) million; andRevenue for the full year 2025 is expected to be in the range of $185.0 million to $205.0 million, unchanged from previous guidance. "Our first quarter revenue exceeded our guidance range, an
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2025 financial and operating results after the market close on Monday, May 12, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 343-4849 or (203) 518-9848 and reference Maravai LifeSciences, Conference ID MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com.
SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2024, together with other business updates. The company also expects to file its Annual Report on Form 10-K for the year ended December 31, 2024, with the Securities and Exchange Commission today. Upon filing, a copy of the annual report will be available on Maravai's website, www.maravai.com, by selecting "Investors" and then "SEC Filings." Key Financial Results: Quarterly revenue of $56.6 million, Ne
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that it is postponing its previously announced earnings release and call scheduled for February 25, 2025. It also announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission and will delay the filing its annual report on Form 10-K for the fiscal year ended December 31, 2024 (the "2024 Form 10-K"). Maravai intends to hold its postponed earnings call and to file the 2024 Form 10-K as soon as practicable and on or
Molecular Assemblies proprietary Fully Enzymatic SynthesisTM technology to enhance mRNA and oligonucleotide manufacturing capabilities within the TriLink BioTechnologies business Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today its acquisition of intellectual property and relevant assets from Molecular Assemblies (MAI). The acquisition will expand Maravai and TriLink BioTechnologies' ability to enable customers to develop next-generation mRNA and CRISPR nucleic acid-based therapies. "Molecular Assemblies is the original leader in enzymatic oligo synthesis, with strong foundational IP.
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that based on preliminary year-end results and subject to year-end closing adjustments, the Company expects to report total 2024 revenue near the mid-point of the previously announced guidance range of $255.0 million and $265.0 million. The Company also announced that it plans to announce its fourth quarter and full year 2024 financial and operating results after the market closes on Tuesday, February 25, 2025, and will host a conference call and webcast on the same day at 2:
Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&D SAN DIEGO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2024, together with other business updates. Financial Highlights: Quarterly revenue of $65.2 million, Net loss of $(176.0) million (including a goodwill impairment of $154.2 million), and Adjusted EBITDA of $12.7 million; andUpdated revenue guidance for the full year 2024 to be in the r
SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2024 financial and operating results after the market closes on Thursday, November 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference Maravai LifeSciences, Conference ID 9502421. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.mara
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2024, together with other business updates. Financial Highlights: Quarterly revenue of $73.4 million, Net loss of $(14.5) million, and Adjusted EBITDA of $16.9 million; andReaffirmed revenue guidance for the full year 2024 in the range of $265.0 million to $285.0 million. Partnerships and Innovation: TriLink BioTechnologies announced a collaboration with the John Hopkins University aimed at accelerating transformationa
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on Wednesday, August 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference Maravai LifeSciences, Conference ID 4292675. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.mara
SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William "Trey" Martin III in these roles. "This leadership transition reflects Maravai's commitment to accelerating innovation, execution, and financial performance. Bernd brings more than 30 years of leadership experience in the life sciences industry, with a proven track record of transforming businesses into profitable, revenue-growing com
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of "Maravai LifeSciencesReleases 2024 Sustainability Report". The corrected title is "Maravai LifeSciences Releases 2024 Sustainability Report". Maravai Lif
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2
SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that its CEO William "Trey" Martin, III has been appointed to the Company's Board of Directors, effective July 31, 2024. This strategic appointment underscores Martin's commitment to innovation, leadership capabilities, and deep industry knowledge. "We are thrilled to welcome Trey to our Board of Directors," said Carl Hull, Maravai's co-founder and Executive Chair of its Board of Directors. "Trey's extensive experience and depth of knowledge will bring valuable perspectives and enrich our collective
William "Trey" Martin, III assumes the role of Maravai's CEO Carl Hull to continue to serve as Executive Chairman SAN DIEGO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that William "Trey" Martin, III has assumed the role of Chief Executive Officer (CEO) of Maravai LifeSciences effective July 27, 2023, consistent with the Company's previously announced CEO succession plan. Carl Hull, Maravai's co-founder and prior interim CEO, will continue to serve as Maravai's Executive Chairman of the Board. "We are thri
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Robert ("Chip") Hance has stepped down from the Company's Board of Directors (the "Board") effective July 19, 2023, and that Dr. John DeFord has been appointed to the Board effective July 20, 2023. Mr. Hance, a 25-year veteran in the medical device industry, is set to become the Chairman of the Board of the Medical Device Innovation Consortium (MDIC) and stepped down from the Board in anticipation of the increased time commitment associated with that role. D
Maravai announces plans for William "Trey" Martin, III to serve as President of its Biologics Safety Testing Segment and its expectation that he will then assume the role of Maravai's CEO in July 2023 Carl Hull to continue to serve as Executive Chairman and Interim CEO SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced plans for William "Trey" Martin, III to serve as President of Maravai's Biologics Safety Testing Segment beginning December 5, 2022, and expects that Martin will assume the role of Chief Executive Officer of Maravai LifeSciences on Ju
William "Trey" Martin, III appointed to succeed Carl Hull as Chief Executive OfficerHull to Serve as Executive Chairman of the Board of Directors SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that its Board of Directors has appointed William "Trey" Martin, III as its chief executive officer (CEO). Mr. Martin comes to Maravai most recently from Danaher Corporation, where he was the Senior Vice President of New Business, Genomic Medicine. Maravai's first CEO and co-founder Carl Hull will directly support Mr. Martin during this leadership tra
EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced the appointment of Jessica Hopfield, Ph.D. to the Berkeley Lights' Board of Directors as an independent director, effective December 15, 2021. "Dr. Hopfield is a respected and accomplished industry veteran, and we are thrilled to welcome her to our Board," said Eric Hobbs, Ph.D., chief executive officer of Berkeley Lights. "With more than two decades of medical device, biotech and pharmaceutical experience, Dr. Hopfield brings to Berkeley Lights valuable strategic insight and a strong focus on performance to drive our unrivaled ability to understand c